- 1 Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven
- 2 immune activation in Sjögren's Disease.
- 3 Sarthak Gupta^{1†}, Eiko Yamada^{2†}, Hiroyuki Nakamura³, Paola Perez², Thomas J.F. Pranzatelli³,
- 4 Kalie Dominick², Shyh-Ing Jang², Mehdi Abed², Daniel Martin⁴, Peter Burbelo⁴, Changyu Zheng⁴,
- 5 Ben French³, Ilias Alevizos², Zohreh Khavandgar^{2,5}, Margaret Beach⁵, Eileen Pelayo⁵, Brian
- 6 Walitt⁵, Sarfaraz Hasni¹, Mariana J. Kaplan^{1,6}, Mayank Tandon², M. Teresa Magone⁷, David E.
- 7 Kleiner⁸, John A. Chiorini³, Alan N. Baer⁵, Blake M. Warner^{2,5†^}
- 8 [†]These authors contributed equally to this work.
- 9 ^ lead and supervised this work
- 10

Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin
 Diseases, National Institutes of Health, Bethesda MD, USA.

- 2. Salivary Disorder Unit, National Institute of Dental and Craniofacial Research, National
 Institutes of Health, Bethesda, MD, USA.
- 3. Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial
 Research, National Institutes of Health, Bethesda, MD, USA.

17 4. Genomics and Computational Biology Core, National Institute of Dental and Craniofacial

18 Research, National Institutes of Health, Bethesda, MD, USA.

19 5. NIDCR Sjögren's Disease Clinic, National Institute of Dental and Craniofacial Research,

- 20 National Institutes of Health, Bethesda, MD, USA.
- 21 6. Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin
- 22 Diseases, National Institutes of Health, Bethesda MD, USA.

- 23 7. Consult Services Section, National Eye Institute, National Institutes of Health, Bethesda MD,
- 24 USA.
- 25 8. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National
- 26 Institutes of Health, Bethesda MD, USA.

27

- 28 Please address correspondence to:
- 29 (A)Sarthak Gupta (sarthak.gupta@nih.gov)
- 30 (B) Eiko Yamada (eiko.yamada@nih.gov)
- 31 (C) Blake M. Warner (blake.warner@nih.gov)

32

- **33 Word Count:** 3994 (< 4000 words)
- 34 Number of Tables: 0
- 35 Number of Figures: 7
- **36 References:** 48

37

38 Abstract

39 **Objectives:** Inflammatory cytokines that signal through the JAK- STAT pathway, especially 40 interferons (IFNs), are implicated in Sjögren's Disease (SjD). Although inhibition of JAKs is 41 effective in other autoimmune diseases, a systematic investigation of IFN-JAK-STAT signaling 42 and effect of JAK inhibitor (JAKi) therapy in SjD-affected human tissues has not been reported. 43 Methods: Human minor salivary glands (MSGs) and peripheral blood mononuclear cells (PBMCs) were investigated using bulk or single cell (sc) RNA sequencing (RNAseq), 44 45 immunofluorescence microscopy (IF), and flow cytometry. Ex vivo culture assays on PBMCs and 46 primary salivary gland epithelial cell (pSGEC) lines were performed to model changes in target 47 tissues before and after JAKi.

Results: RNAseq and IF showed activated JAK-STAT pathway in SjD MSGs. Elevated IFNstimulated gene (ISGs) expression associated with clinical variables (e.g., focus scores, anti-SSA
positivity). scRNAseq of MSGs exhibited cell-type specific upregulation of JAK-STAT and ISGs;
PBMCs showed similar trends, including markedly upregulated ISGs in monocytes. *Ex vivo*studies showed elevated basal pSTAT levels in SjD MSGs and PBMCs that were corrected with
JAKi. SjD-derived pSGECs exhibited higher basal ISG expressions and exaggerated responses to
IFNβ, which were normalized by JAKi without cytotoxicity.

55 Conclusions: SjD patients' tissues exhibit increased expression of ISGs and activation of the JAK56 STAT pathway in a cell type-dependent manner. JAKi normalizes this aberrant signaling
57 at the tissue level and in PBMCs, suggesting a putative viable therapy for SjD, targeting both
58 glandular and extraglandular symptoms. Predicated on these data, a Phase Ib/IIa randomized
59 controlled trial to treat SjD with tofacitinib was initiated.

60

61 Key messages (total 3-5 sentences)

62 What is already known on this topic?

- Upregulation of interferons (IFNs) has been reported in patients with SjD; however, a
 systematic investigation of their role at a cellular and tissue level in humans is lacking.
 What this study adds?
- Our findings conclusively show that the IFN-JAK-STAT pathway is activated in the
 salivary glands and PBMCs in patients with SjD
- Specific cells in the MSGs (infiltrating lymphocytes, epithelial, antigen presenting cells,
 and endothelial cells) and in PBMCs (monocytes, NK cells, and dendritic cells) drive this
 IFN signature.
- We pinpoint cells responsive to JAK inhibition and illustrate in patient tissues that JAK
 inhibitors may be beneficial in SjD by uncoupling the pathogenic cytokine milieu and
 resultant epithelial tissue damage and dysfunction central to SjD.

74 How this study might affect research, practice, or policy?

SjD lacks an approved, efficacious and targeted therapy. Several large clinical trials have
 been unsuccessful due in part to a lack of biologically relevant endpoints or predictive
 biomarkers. We establish a multimodal testing platform using human tissues from SjD
 patients to identify actionable targets and to directly test treatment effects. Our data suggest
 that blocking the IFN-JAK-STAT pathway by using JAKi is a rational therapy for SjD.
 Moreover, these data can also serve as biological endpoints for clinical trials
 [NCT04496960].

- 82
- 83 Keywords (< 5): Sjögren's Disease, Interferon, Janus kinases, STAT, Tofacitinib

84 Introduction

Despite being the second most common systemic autoimmune rheumatic disease, Sjögren's Disease (SjD) lacks a precise etiology or an approved and efficacious therapy that meaningfully manages symptoms or alters disease progression.¹ Concerted efforts have been expended toward identifying the pathogenic mechanisms of SjD; these efforts have led to the development and testing of many medications to treat SjD.² However, few agents met their primary endpoints until very recently, and only limited biological data accompany these studies.²

One of the reasons for these limitations could be the heterogeneous clinical presentation of patients with SjD. Chronic inflammatory lymphocytic infiltration of the exocrine glands leading to dysfunction and ultimate destruction of the tissue is characteristic of SjD. Most SjD patients present with symptoms involving the salivary and lacrimal glands. Other tissues that can be affected include: the skin; the respiratory tract nervous system, kidneys, and the vagina, along with systemic symptoms including fatigue, widespread musculoskeletal pain, and polyarthritis.³⁴

Many of the inflammatory cytokines implicated in SjD pathogenesis, in particular Type-I
and Type-II interferons (IFNs), interleukins (IL)-6, IL-7, IL-12, and IL-21, signal through the
Janus Kinases (JAK)-Signal Transducer and Activator of Transcription (STAT) pathway.⁵
However, a comprehensive understanding of IFN signaling and the involvement of the JAK-STAT
pathway in SjD tissues is lacking. Clarification of cell types driving disease pathogenesis in the
peripheral blood and in the salivary glands will facilitate the development of targeted therapies for
SjD.

In this study, we aimed to characterize JAK-STAT pathway utilization in SjD-affected tissues and establish a human-tissue-based experimental rationale for examining the efficacy of JAK inhibitors (JAKi) in SjD participants. We used an 'omics' platform to identify high-potential

107 tractable pathways in the affected tissue compartments in SjD. We first performed 'bulk' RNA 108 sequencing (RNAseq) on minor salivary glands (MSGs) from patients with SjD and demonstrated 109 activation of the JAK-STAT pathway. These findings were corroborated using immunofluorescent 110 staining (IF) of salivary glands, and flow cytometry analysis of the salivary glands and peripheral 111 blood mononuclear cells (PBMCs) from patients with SjD. Using single cell RNAseq (scRNAseq), 112 we were able to identify cells in the glands and peripheral blood that upregulate IFNs through the 113 JAK-STAT pathway in MSGs and then confirmed these findings using flow cytometry and ex vivo 114 culture assays. Finally, we used patients' tissues and primary cell models to show that JAKi can 115 correct this altered pathway activation without cytotoxicity as a high-potential targeted therapy for 116 SjD.

117

118 Materials and Methods

119 Subjects and ethical approval

120 Study subjects provided informed consent prior to the initiation of any study procedure, 121 and they were evaluated and classified comprehensively according to 2016 American College of 122 Rheumatology (ACR) and the European League Against Rheumatism (EULAR) classification 123 criteria.⁶ Comparator group included subjects who did not meet 2016 ACR-EULAR criteria (non-SjD) or healthy volunteers (HV).⁷ All subjects were screened for evidence of systemic 124 125 autoimmunity and received comprehensive oral/sialometric, rheumatological, and 126 ophthalmological investigations. Clinical investigations were conducted in accordance with the 127 Declaration of Helsinki principles. All studies using human samples were approved by the NIH 128 IRB (15-D-0051, NCT00001390; 11-D-0172, NCT02327884, or 94-D-0018, NCT00001196; PI-129 Warner).

130 Patient and Public Involvement

- 131 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination
- 132 plans of our research.
- 133 Human Salivary Gland RNA Sequencing
- 134 Bulk RNA sequencing was performed as previously described.⁸ RNAseq data that passed quality
- 135 control was deposited in dbGaP: phs001842.v1.p1.
- 136 Single Cell RNA Sequencing of the MSGs and PBMCs
- 137 MSG biopsies and PBMCs were processed for scRNAseq as previously described (supplemental
- **table 1**).^{9 10} scRNAseq data sets were analyzed in Python using Scanpy.
- 139 Immunofluorescence microscopy and analysis on MSGs
- 140 Detection of JAK1 and JAK3 in MSG. FFPE MSG sections were processed following standard
- 141 procedures. Sections were blocked, incubated in antibodies, and mounted (**supplemental table 2**).
- 142 Immunofluorescence in primary cell culture assays. Primary salivary gland epithelial cells
- 143 (pSGECs) were plated on chamber slides and stimulated as indicated, then stained with antibodies
- 144 (supplemental table 2). Images were acquired on Nikon A1 HD (Nikon) confocal microscope
- and processed with CellProfiler in ImageJ (Broad Institute).¹¹
- 146 *Flow cytometry*
- 147 Freshly biopsied MSGs were dissociated as described above. Multicolor flow cytometry was used
- to quantify the phosphorylation status of pSTATs in gated cell subset populations (supplemental
- 149 **table 2** and **supplemental method 1, 2**).
- 150 Assessment of serum proteome

151	Proteomic profiles were measured in serum (50 μ L) using the SOMAscan Assay V1.3 (SomaLogic,
152	Inc.) at the Trans-NIH Center for Human Immunology, Autoimmunity, and Inflammation,
153	National Institutes of Health as previously reported. ¹²
154	RNA isolation and RT-qPCR
155	Standard Taqman assays (supplemental table 3) were performed to measure relative gene
156	expression.
157	Statistical Analysis for Difference in Immune Cell Populations/Cytokines
158	Statistical methods were employed using GraphPad Prism (GraphPad), MATLAB, or -R as
159	described, and the type and nature of the data were considered when assessing differences in mean
160	values and variances across biological and experimental replicates. A p -value of <0.05 was
161	considered statistically significant.
162	
163	Results
164	Genes in the JAK-STAT and Type-I IFN pathways are upregulated in MSGs from patients with
165	SjD
166	To understand the transcriptome wide impacts of SjD on the MSGs, we first performed
167	'bulk' RNAseq on SjD and HV MSGs (figure 1A). Unsupervised clustering generally segregated
168	SjD from HV MSGs based on differentially expressed genes (DEGs) (figure 1B, C). MSGs from
169	SjD subjects were transcriptionally more active. Immune pathway genes, including ISGs (e.g.,
170	IFI44L, IFI44, MX1, CXCL13), were upregulated in SjD whereas canonical salivary genes were

downregulated (figure 1B, C). Pathway enrichment analysis identified the JAK-STAT Pathway as

one of the top significantly and differentially utilized pathway in SjD (figure 1D). Gene

enrichment analysis showed consistent and direct regulation of the JAK-STAT pathway signaling

171

172

173

8

174 through *IL7/IL15/IL21* via *JAK3* (supplemental figure 1B). We examined the mRNA expression 175 of JAK genes and found that JAKI had the highest expression in all MSGs whether they were from 176 SjD or HV. However, when comparing MSGs from SjD to those from HV, JAK2 and JAK3, but 177 not JAK1 or TYK2, expression was differentially increased (supplemental figure 1C). 178 Although the bulk RNAseq was unable to reliably detect Type-I IFN transcripts, these data 179 demonstrated increased IFNG (supplemental figure 1D). Thus, we employed surrogate readouts of Type-I and Type-II IFN gene expression using validated composite Type-I (21-gene)^{13 14} and 180 Type-II (8-gene)¹⁵⁻¹⁷ IFN scores to demark patients with enhanced JAK-STAT pathway signaling. 181 Calculated Type-I and Type-II IFN scores¹⁸ revealed 2-fold and 2.5-fold mean increases, 182 183 respectively, in SjD patients' MSGs compared to HV glands (p=0.0033 and p=0.0009, 184 respectively; figure 1E, G). Of the 24 SjD subjects, 17 (71%) had elevated Type-I or Type-II ISG 185 scores; 7 exhibited elevations in both Type-I and Type-II IFN ISGs; while 5 each exhibited

elevated Type-I or Type-II ISGs. Seven did not show significant elevation of either and were
enriched for anti-SSA antibody negative subjects (5/7) (figure 1E, G). Type-I and Type-II ISG
scores exhibited modest, positive, statistically significant correlation, but not all the variance was
explained.

Increased lymphocytic infiltration, quantified as a focus score (FS), is an independent predictor of deterioration of exocrine gland function.¹⁹ SjD is related to both loss of epithelial cells and greater inflammation in the glands. The Type-I and Type-II IFN scores from our bulk RNAseq positively correlated with FS in the glands; however, Type-II IFN exhibited a stronger correlation than Type-I IFN ($R^2=0.24$, p=0.0031 and $R^2=0.65$, p<0.0001, respectively; **figure 1F, H**). Our data suggests that Type-II IFN signature serves as a surrogate for IFN γ produced by T cells in the glands; while Type-I IFN signaling is appreciably more disease-specific and integrates the

197 contributions of the epithelial cells, dendritic cells, and monocytes in the MSG. Moreover, it is 198 well-documented that there is positive crosstalk between Type-I IFNs (α and β) and Type-II IFN 199 (γ) receptor signaling. In our cohort most patients exhibited elevated Type-I signaling. Thus, we 200 focused on Type-I signaling in subsequent experiments, acknowledging that signaling *in vivo/in* 201 *situ* is far more complex.

These findings confirm that SjD pathogenesis involves IFN-JAK-STAT pathway. However, "bulk" RNAseq does not precisely and robustly predict the compositional cell types or infer the cell states changes contributing to these phenomena in SjD-affected MSG.

205

206 Expression of JAK1 and JAK3 in the salivary glands is cell type-specific

207 To pinpoint the cell types and expression levels of JAK1 and JAK3 in the MSG, we used 208 IF, whole slide imaging and analysis, and tSNE visualization (figure 2A). These results revealed 209 the expected cellular proportion changes in the MSGs. Keratin-18 expression was restricted to 210 epithelial structures (+6%, *p*<0.001; figure 2B, C and supplemental figure 2A-C). Per-cell JAK1 211 expression was mildly elevated in immune cells in SjD, while per-cell JAK3 expression showed 212 both SjD-specific increased per-cell expression in epithelial cells and infiltrating immune cells in 213 SiD (+35%, p < 0.0001 and +15%, p < 0.0001, respectively; figure 2C). It is generally assumed that 214 high IFN signaling is driven by infiltration of immune cells; however, the IF and RNAseq results 215 independently confirm that signaling is directed in part by the involved epithelium.

216

217 Increased phosphorylated STAT proteins in SjD MSGs confirm activation of JAK-STAT
218 pathway

219	To directly confirm the activation status of the JAK-STAT pathway in MSGs, we measured
220	the frequency of pSTAT proteins by flow cytometry in freshly biopsied and dissociated MSGs
221	(figure 2A). In general, flow cytometry exhibited cellular proportion changes consistent with the
222	IF results in the glands (figure 2D). The frequency of pSTAT1, pSTAT3(Ser727) and pSTAT6
223	proteins were higher at baseline in SjD epithelial cells compared to non-SjD (2.0-fold, $p=0.017$;
224	2.9-fold, $p=0.028$; and 6.9-fold, $p=0.1080$, respectively; figure 2E), directly supporting elevated
225	activation of the JAK-STAT pathway in SjD epithelial cells. Moreover, the frequency of pSTAT
226	proteins on immune cells showed a similar pattern in SjD-affected MSGs (1.4-fold, $p=0.3749$; 2.6-
227	fold, $p=0.068$; and 1.2-fold, $p=0.3499$, respectively; figure 2E), with appreciably less significant
228	differences.

229

High IFN signature and activated JAK-STAT pathway in SjD MSGs is due to salivary gland epithelial and infiltrating immune cells

Our results implicate coordinated interactions between the epithelium and the immune 232 233 infiltrate (i.e., autoimmune epithelitis).³ To better understand the transcriptional impact of SjD on 234 each cell type, we then analyzed single cell transcriptomes from MSGs from SjD and non-SjD 235 subjects. Leiden clustering of scRNAseq data identified 11 clusters of cells representing the 236 general cell types in the MSGs (figure 3A and supplemental figure 3A, C). Expectedly, compared 237 to non-SjD MSGs—and consistent with both the IF and flow cytometry results—the proportion of 238 seromucous acinar cells was reduced and immune cell infiltration was increased in SjD (figure 239 **3B**). Examining the top ten DEGs in each of the cell types demonstrated that SjD cells were 240 dominated by ISGs (figure 3C). A Type-I IFN score was calculated for all cells in SjD and non-241 SjD and was increased in all cells in SjD patients' glands (figure 3D). Moreover, seromucous

acinar cells showed increased expression of multiple *JAK* genes, while ductal cells had increased
expression of *JAK3* and *TYK2* (figure 3E and supplemental figure 3C, D). These results
independently confirm our bulk and proteomics data and suggest that disease-specific utilization
of this pathway in unique cell types.

246

247 Sera from SjD have increased IFN Signature

248 As a prototypic systemic autoimmune disease, additional non-exocrine organs are also 249 commonly affected in SjD. To estimate proteomic changes in the circulation, Somalogic aptamer-250 based 1.3K target proteomics was performed. Most proteins were significantly upregulated in sera 251 from SjD patients compared to controls (figure 4B). Consistent with MSGs data, inflammation 252 and IFN regulated proteins were upregulated in sera. A validated 4-protein IFN score demonstrated 253 a significant increase of IFN-stimulated proteins in SjD patients' sera compared to both non-SjD 254 and HV sera (p < 0.0001; figure 4C). These data indicate that IFN signatures in the glands are 255 recapitulated in the blood and suggest similar pathogenic mechanisms affecting both tissue 256 compartments.²

257

258 scRNA of PBMCs identify cells with activated JAK-STAT pathway

To better understand the transcriptional impact of SjD on each cell type in the peripheral blood, single-cell transcriptomes from PBMCs from SjD and non-SjD subjects were analyzed. scRNAseq identified 10 unique general types by Leiden clustering (**figure 4D** and **supplemental figure 4A, B**). DEG analysis showed upregulation of many ISGs (e.g., *IF144L, IF1T3, ISG15, MX1,* and *IF16*) in SjD PBMCs (**supplemental figure 4C**). Functional annotation analysis revealed that upregulated genes were mostly associated with immune and inflammatory responses, especially

'innate immunity against virus' and '*Type-I IFN responses*' (figure 4E). Type-I IFN scores were
projected on to each cell and were higher in SjD PBMCs compared to controls (figure 4F).
Monocytes had the highest expression of ISGs in SjD, followed by dendritic cells, and then NK
cells (figure 4F).

269

270 Increased phosphorylated STAT proteins in SjD PBMCs confirmed activation of JAK-STAT 271 pathway in blood

272 To directly estimate the activation of the JAK-STAT pathway in the blood, the frequencies 273 of pSTAT proteins were measured by flow cytometry of PBMCs from patients with SjD and HVs. 274 The frequencies of basal pSTAT proteins, pSTAT1, pSTAT3(Ser727) and pSTAT6, were higher 275 in SjD patients compared to HVs (2.0-fold, p=0.007, 2.3-fold, p=0.046, and 1.3-fold, p=0.044, 276 respectively; figure 5 and supplemental figure 5). Of note, pSTAT3(Ser727), but not 277 pSTAT3(Tyr705) was significantly upregulated in SjD patients. In aggregate, these findings 278 indicate that enhanced Type-I IFN response in PBMCs could be involved in both the systemic 279 aspect of SjD and local inflammation after infiltration into the MSGs. Our results suggest that we 280 could employ this tissue as a surrogate model for assessing if identified drugs are biologically 281 effective for SjD or stratify patients amenable to pathway targeting, a priori.

282

283 Tofacitinib inhibits Type-I IFN response in PBMCs

Based on our transcriptomic and proteomic data, SjD pathogenesis may be selectively dependent on JAK3 and JAK1 in both immune and epithelial compartments. Thus, we tested the effectiveness of the JAK3/JAK1 semi-selective inhibitor, tofacitinib, in *ex vivo/in vitro* assays (**figure 6A**). Treatment with 5 µM tofacitinib blocked STATs phosphorylation status induced by

288 IFN β stimulation in PBMCs in all cell subsets without inducing cytotoxicity (figure 6B and 289 supplemental figure 6A, D). scRNAseq showed that 5 µM tofacitinib downregulated 109 DEG, 290 nearly all of which were ISGs, and no genes were upregulated. Tofacitinib suppressed the IFNβ-291 induced IFN signature to baseline levels (figure 6C, D and supplemental figure 6B). Cell clusters 292 with sufficient number of representation of samples and cells in each treatment group cluster were 293 analyzed for top DEG by pseudobulk analysis. T cells and monocytes exhibited greater numbers 294 of downregulated ISGs in the context of tofacitinib inhibition. ISGs were among the top DEG in 295 all subsets after IFNB stimulation and tofacitinib normalized this response; cell type-specific 296 effects were less dominant (figure 6E). A similar direction of effect was shown in PBMCs treated 297 with $5\mu M$ to facitinib without IFN β stimulation, though there was appreciable inter-individual 298 variability in responsiveness to tofacitinib (supplemental figure 6C). These data provide clear 299 and direct evidence, using affected human tissues from SjD patients, that in vitro tofacitinib can 300 abrogate basally activated JAK-STAT signaling and suggest that responsiveness to JAK inhibition 301 is somewhat SjD-selective. These results raised the question as to whether a similar correction 302 could be achieved in glandular epithelial cells.

303

304 Tofacitinib, a JAK inhibitor, reduces Type-I IFN response in primary salivary gland epithelial
305 cells

To model the glandular epithelial response to Type-I IFN and blockade by tofacitinib, we used primary salivary gland epithelial cells derived and cultured from SjD and HV. Tofacitinib at 5μ M concentration did not induce apoptosis or necrosis in pSGEC (**supplemental figure 7A, B**). Tofacitinib mitigated IFNβ-induced pSTAT1 proteins in both the nucleus and cytosol in pSGECs as assessed by IF (0.78-fold, *p*<0.0001; 0.84-fold, *p*<0.0001, respectively; **figure 7B**), and dose-

311	dependently decreased IFN β -induced ISGs mRNA expression (<i>CXCL10</i> : 0.002-fold, $p=0.023$;
312	<i>ISG15</i> : 0.03-fold, <i>p</i> =0.003; <i>MX1</i> : 0.01-fold, <i>p</i> =0.009; figure 7C and supplemental figure 7C).
313	Of note, SjD-derived pSGECs exhibited an enhanced response to IFN β stimulation (e.g., <i>CXCL10</i> :
314	33.6-fold, $p=0.032$; figure 7C). pSGECs treated with tofacitinib without IFN β stimulation showed
315	a trend towards decreased expression of ISGs, though this was not statistically significant
316	(supplemental figure 7D). These results suggest that i) responsiveness to JAK inhibition is
317	activation-dependent and SjD-selective, and <i>ii</i>) while activation is not retained in pSGECs in vitro,
318	pSGECs do retain SjD-specific enhanced responsiveness to IFN stimulation ²⁰ supporting the
319	robustness of this model system.

320 Discussion:

321 Current strategies for managing SjD are ineffective in limiting disease progression or preventing the long-term decline in quality of life. Recent successes of early stage randomized 322 323 controlled trials in SjD (BAFF-R, TACI, CD40, CD40L²¹) offer renewed optimism to patients and 324 providers. Given the multiple intersecting pathogenic pathways driving varied clinical 325 presentations in SjD, and a paucity of successful trials, there is continued need for biologically 326 relevant, effective, and targeted therapeutics. Rational repurposing of approved drugs offers an 327 exciting path to accelerate the approval of safe and effective medications for patients with SiD. To 328 this end, we established a multimodal testing platform using human tissues from SjD patients to 329 identify actionable targets and to directly test biological effects. Specifically, we hone-in on Type-330 I IFN signaling through the JAK-STAT pathway.

331 The activation of the IFN pathway in SjD patients' peripheral blood has been reported²², 332 but the specific cell types driving this upregulation in blood or in the glands remain poorly detailed. 333 Using transcriptomic and functional approaches on peripheral blood and MSG tissue from SjD 334 patients, our data revealed enhanced IFN signaling via JAK-STAT in both compartments, 335 emphasizing the therapeutic potential of this pathway. We identified cell subsets driving this 336 activated state: monocytes, NK cells and DCs in PBMCs and infiltrating immune cells and salivary 337 gland epithelial cells in MSGs. Our data confirm SjD-specific upregulation of ISGs and JAK-STAT pathway in salivary glands and blood, aligning with previous reports.²³ These cytokines, 338 via Janus Kinases, initiate and enhance inflammation in SjD salivary glands.^{2 24-28} Similar to a 339 340 previous report, the elevated IFN signatures in MSG correlated with clinical variables including focus score and enrichment in autoantibody-positive subjects.²⁹ 341

342 To understand the upstream effects in SjD-affected MSG, we measured JAK genes and 343 protein expression in the glands at single cell resolution. Among the JAK genes expressed in the 344 MSGs, JAK1 was most abundant and ubiquitously expressed in both SjD and non-SjD. However, 345 JAK3 mRNA and protein expression was only elevated in SjD. Using IF on MSGs, JAK1 protein 346 localized to immune and epithelial cells with a very slight increased expression (~6%) in SjD 347 immune cells likely due to increased expression in APCs as found in scRNAseq. Confirming our 348 bulk and scRNAseq data, IF showed that JAK3 protein was increased in i) the ductal and acinar 349 epithelium in SjD involved by focal lymphocytic inflammation, and *ii*) in inflammatory cells 350 within inflammatory foci. A previous report showed JAK1 staining in ductal cells, and to a lesser extent in acinar cells, in HV and SjD patients.³⁰ We extend the understanding of JAK-STAT 351 352 signaling in the gland by showing the novel finding of disease-specific dependence of JAK3 353 signaling in the ductal epithelium. These data provide guidance for rational drug selection (i.e., a 354 JAK3/JAK1 targeting drug such as tofacitinib) whereby the epithelium and disease-specific 355 immune infiltrates show evidence of dependence on JAK-STAT signaling through JAK3/JAK1 in 356 SjD.

Deciphering the JAK-STAT pathway involvement in SjD is an exciting area of 357 358 investigation. We and others have demonstrated significantly increased *IL21* and IL-21-inducible genes: JAK3 and STAT1 in SjD via RNAseq of MSGs.³¹ pSTAT1 in SjD MSG biopsies has been 359 associated with IFN-a, IFN-y, and IL-6 stimulation.^{32 33} Very recently, pSTAT1 was shown to 360 361 confer histopathological value in MSGs with or without lymphocytic foci³⁴; however, these 362 findings are based on weak intensity immunohistochemical staining of pSTAT1 without rigorous 363 quantification. We now directly confirmed that pSTAT1 and pSTAT3(Ser727) are elevated in the 364 epithelial and immune cells in the MSGs by phospho-flow cytometry from SjD subjects. It has

been reported that STAT protein expression is increased in immune cells of MSG.^{32 33 35}
Furthermore, our transcriptomic (bulk and sc) results show that STATs gene expressions are
upregulated in SjD, and our proteomic data establishes that the levels of pSTATs are higher in SjD
MSG than controls. These data further confirm that activated JAK-STAT signaling is a potentially
targetable pathogenetic factor for SjD.

370 Our data supports that activation of IFN pathway in SjD is a systemic phenomenon and not 371 constrained to the salivary glands.³⁶ Enhanced IFN response in PBMCs could be involved in both 372 the systemic features of SjD and local inflammation after infiltration into MSGs. T cells could 373 proliferate locally in the salivary glands, but much of their infiltration is from migration from the 374 circulation.³⁶ In PBMCs from SjD subjects, pSTAT1 frequency was significantly higher compared 375 to controls and was more of a general phenomenon across multiple cell subsets. On the other hand, 376 pSTAT3(Ser727), but not -(Tyr705), were more frequently phosphorylated in SjD T cells, NK 377 cells, and monocytes (supplemental figure 5). pSTAT3(Ser727) has been suggested to contribute 378 to oxidative phosphorylation in the mitochondria with an effect that is independent of 379 STAT3(Tyr705) phosphorylation.³⁷ Davies et al.³⁸ showed increased responses from B cells in 380 peripheral blood from patients with SjD to TLR-7 and -9 agonism were dependent upon 381 phosphorylation of STAT3 at the Ser727 site. It has been reported that Tyr705 phosphorylation is 382 essential for STAT dimerization, nuclear translocation and DNA binding, whereas C-terminal Ser727 phosphorylation is required for maximal transcriptional activity.³⁹ The increased response 383 384 was found to be correlated with Type-I IFN signature suggesting that pSTAT3(Ser727) plays a 385 key role in IFN signaling in SjD patients and could be a potential molecule for targeted therapy or 386 to monitor therapeutic effects of targeted therapies. These results support *i*) the independence of

387 Ser727 from Tyr705 on pSTAT3, and *ii*) possibly highlight patients with maximal pathway
388 activation who may benefit from JAKi.

JAKi have emerged as an important new class of oral therapy for several autoimmune 389 diseases.^{40 41} Tofacitinib was the first oral JAK inhibitor approved for rheumatoid arthritis. It 390 blocks JAK3 and JAK1 but also has a role in JAK2 and TYK2 inhibition.⁴²⁻⁴⁶ Our ex vivo 391 392 experiments using pSGECs and PBMCs consistently demonstrated that tofacitinib treatment 393 suppressed JAK-STAT pathway activation in a dose-dependent manner, as shown by 394 downregulated pSTAT levels, decreased IFN signature and ISG expression. Of note, basal 395 elevations in pSTAT levels were selectively controlled by tofacitinib in SjD patients' PBMCs, but 396 not controls. Similar to our results, recently baricitinib, a semi-selective inhibitor of JAK1 and 397 JAK2, mitigated IFN-γ-induced CXCL10 production in salivary gland ductal cell line.³⁰

398 Cell type differences in responsiveness have been reported with regards to the potency of 399 JAKi to inhibit cytokine signaling. A 3-fold difference was observed in the JAK1/TYK2-400 dependent IFN-stimulated pSTAT1 between CD4+ T cells and monocytes, whereas the potencies 401 were comparable for B and NK cells.⁴⁷ For the reactivity of each pSTAT, JAK inhibition of JAK1/TYK2-mediated IFNa-driven pSTAT5 and pSTAT3 was more potent than pSTAT1, 402 potentially demonstrating the reliance on TYK2 for regulating STAT1 phosphorylation.⁴⁸ In our 403 404 study, pSTATs (e.g., pSTAT1, pSTAT3(Ser727), pSTAT6) in T cells showed consistent 405 sensitivity to JAKi treatment. Other cell subsets also demonstrated pSTAT specific sensitivity (B 406 cells - pSTAT1; NK cells-pSTAT1/6). Our findings suggest that pathogenic inflammatory 407 signaling through specific JAKs may identify selective therapeutic drug choice.

408 Limitations of this study include relatively modest sample sizes used for fresh tissue409 analyses. The prospective use of fresh tissues poses logistical challenges including recruitment and

19

adequate tissue recovery for both clinical and research purposes. Despite these limitations, we
demonstrate biologically meaningful changes in JAK-STAT pathway in glandular and peripheral
blood samples and direct responsiveness to JAKi. These limitations are addressed by using
multiple different experimental approaches to systematically and comprehensively evaluate the
IFN-JAK-STAT pathway in SjD.

415 In conclusion, SjD patients have increased IFN signature with activated JAK-STAT 416 pathway which plays a key role in both the glandular and extraglandular pathogenesis of SjD. This 417 activation is cell specific, with salivary epithelial cells and infiltrating immune cells driving the 418 bulk of this signature in MSGs. The activated IFN-JAK-STAT signature is also seen in peripheral 419 blood, highlighting the dysregulated systemic immune system in SjD. Modulation of the JAK-420 STAT pathway, through JAKi was non-cytotoxic and effective ex vivo using human tissues. These 421 results suggest to facitinib as a potential therapeutic strategy for SjD patients and serve as the basis 422 of an open and enrolling Phase Ib/IIa randomized controlled trial to treat SjD with tofacitinib 423 (NCT04496960).

424 Potential Conflicts of Interest: BMW has Cooperative Research Award and Development 425 Agreements [CRADA] from Pfizer, Inc., and Mitobridge, Inc. (A subsidiary of Astellas Pharma, 426 Inc.). NIAMS has CRADAs with Astra Zeneca and Bristol Myers Squibb. These CRADA did not 427 financially support the experimental results presented herein. 428 429 Funding/Support: This research was principally supported through research awards to BMW 430 from the Division of Intramural Research (DIR) Program of the National Institute of Dental and 431 Craniofacial Research of the National Institutes of Health (NIH/NIDCR ZIA: DE000704). 432 Additional funding and support from the DIR Program of the National Institute of Arthritis and 433 Musculoskeletal and Skin Diseases of the NIH (NIH/NIAMS ZIA: AR041199). 434 435 Acknowledgements: The authors provide their emphatic appreciation to the subjects for their 436 unwavering support of our clinical studies through their volunteerism. We also thank the support

- 437 and staff of the NIDCR Office of the Clinical Director, NIDCR Dental Clinic, the National Eye
- 438 Institute Ophthalmology Clinic, and the NCI Center for Cancer Research Anatomic Pathology.

439 **References**

- 440 1. Mavragani CP, Moutsopoulos HM. Sjögren's syndrome: Old and new therapeutic targets. J
 441 Autoimmun 2020;110:102364. doi: 10.1016/j.jaut.2019.102364 [published Online First:
 442 20191209]
- 443 2. Hall JC, Baer AN, Shah AA, et al. Molecular Subsetting of Interferon Pathways in Sjögren's
 444 Syndrome. *Arthritis Rheumatol* 2015;67(9):2437-46. doi: 10.1002/art.39204
- 3. Moutsopoulos HM. Sjögren's syndrome: autoimmune epithelitis. *Clin Immunol Immunopathol*1994;72(2):162-5. doi: 10.1006/clin.1994.1123
- 447 4. Mariette X, Criswell LA. Primary Sjögren's Syndrome. *N Engl J Med* 2018;378(10):931-39.
 448 doi: 10.1056/NEJMcp1702514
- 5. Gandolfo S, Ciccia F. JAK/STAT Pathway Targeting in Primary Sjögren Syndrome. *Rheumatol Immunol Res* 2022;3(3):95-102. doi: 10.2478/rir-2022-0017 [published
 Online First: 20221020]
- 6. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. *Arthritis Rheumatol* 2017;69(1):35-45. doi: 10.1002/art.39859 [published Online First: 20161026]
- 457 7. Warner BM, Baer AN, Lipson EJ, et al. Sicca Syndrome Associated with Immune Checkpoint
 458 Inhibitor Therapy. *Oncologist* 2019;24(9):1259-69. doi: 10.1634/theoncologist.2018459 0823 [published Online First: 20190417]
- 460 8. Jang S-I, Tandon M, Teos L, et al. Dual function of miR-1248 links interferon induction and
 461 calcium signaling defects in Sjögren's syndrome. *eBioMedicine* 2019;48:526-38. doi:
 462 10.1016/j.ebiom.2019.09.010
- 463 9. Huang N, Pérez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. *Nat Med*464 2021;27(5):892-903. doi: 10.1038/s41591-021-01296-8 [published Online First:
 465 20210325]
- 466 10. Yin H, Pranzatelli TJF, French BN, et al. Sclerosing Sialadenitis Is Associated With Salivary
 467 Gland Hypofunction and a Unique Gene Expression Profile in Sjögren's Syndrome. *Front*468 *Immunol* 2021;12:699722. doi: 10.3389/fimmu.2021.699722 [published Online First:
 469 20210730]
- 470 11. Stirling DR, Swain-Bowden MJ, Lucas AM, et al. CellProfiler 4: improvements in speed,
 471 utility and usability. *BMC Bioinformatics* 2021;22(1):433. doi: 10.1186/s12859-021472 04344-9 [published Online First: 20210910]
- 473 12. Candia J, Cheung F, Kotliarov Y, et al. Assessment of Variability in the SOMAscan Assay.
 474 *Sci Rep* 2017;7(1):14248. doi: 10.1038/s41598-017-14755-5 [published Online First:
 475 20171027]
- 476 13. Yao Y, Higgs BW, Morehouse C, et al. Development of Potential Pharmacodynamic and
 477 Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus
 478 Erythematosus. *Hum Genomics Proteomics* 2009;2009 doi: 10.4061/2009/374312
 479 [published Online First: 20091117]
- 480 14. Gupta S, Tatouli IP, Rosen LB, et al. Distinct Functions of Autoantibodies Against Interferon
 481 in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine
 482 Autoantibodies in Common Rheumatic Diseases. *Arthritis Rheumatol* 2016;68(7):1677-
- 482 Autoantibodies in Common Rneumatic Diseases. Arthritis Rheumatol 2016;68(7):1677-
- 483 87. doi: 10.1002/art.39607

- 484 15. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. *Arthritis Res* 485 *Ther* 2003;5(6):279-87. doi: 10.1186/ar1015 [published Online First: 20031013]
- 486 16. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a
 487 subgroup of systemic lupus erythematosus patients with distinct serologic features and
 488 active disease. *Arthritis Rheum* 2005;52(5):1491-503. doi: 10.1002/art.21031
- 489 17. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature
 490 in peripheral blood cells of patients with severe lupus. *Proc Natl Acad Sci U S A*491 2003;100(5):2610-5. doi: 10.1073/pnas.0337679100 [published Online First: 20030225]
- 492 18. Smith MA, Chiang CC, Zerrouki K, et al. Using the circulating proteome to assess type I
 493 interferon activity in systemic lupus erythematosus. *Sci Rep* 2020;10(1):4462. doi:
 494 10.1038/s41598-020-60563-9 [published Online First: 20200310]
- 495 19. Haldorsen K, Moen K, Jacobsen H, et al. Exocrine function in primary Sjögren syndrome:
 496 natural course and prognostic factors. *Ann Rheum Dis* 2008;67(7):949-54. doi:
 497 10.1136/ard.2007.074203 [published Online First: 20071025]
- 498 20. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role
 499 in health and disease. *Nat Rev Immunol* 2020;20(6):375-88. doi: 10.1038/s41577-020500 0285-6 [published Online First: 20200304]
- 501 21. Seror R, Nocturne G, Mariette X. Current and future therapies for primary Sjögren
 502 syndrome. *Nature Reviews Rheumatology* 2021;17(8):475-86. doi: 10.1038/s41584-021503 00634-x
- Marketos N, Cinoku I, Rapti A, et al. Type I interferon signature in Sjögren's syndrome:
 pathophysiological and clinical implications. *Clin Exp Rheumatol* 2019;37 Suppl
 118(3):185-91. [published Online First: 2019/08/04]
- 507 23. Nordmark G, Alm GV, Rönnblom L. Mechanisms of Disease: primary Sjögren's syndrome
 508 and the type I interferon system. *Nat Clin Pract Rheumatol* 2006;2(5):262-9. doi:
 509 10.1038/ncprheum0173
- 24. Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjogren's
 syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's
 related lymphomagenesis. *J Autoimmun* 2015;63:47-58. doi: 10.1016/j.jaut.2015.07.002
 [published Online First: 20150714]
- 514 25. Soret P, Le Dantec C, Desvaux E, et al. A new molecular classification to drive precision
 515 treatment strategies in primary Sjögren's syndrome. *Nat Commun* 2021;12(1):3523. doi:
 516 10.1038/s41467-021-23472-7 [published Online First: 20210610]
- 26. Ha YJ, Choi YS, Kang EH, et al. Increased expression of interferon-λ in minor salivary glands of patients with primary Sjögren's syndrome and its synergic effect with interferon-α on salivary gland epithelial cells. *Clin Exp Rheumatol* 2018;36 Suppl 112(3):31-40. [published Online First: 2017/04/20]
- 521 27. Båve U, Nordmark G, Lövgren T, et al. Activation of the type I interferon system in primary
 522 Sjögren's syndrome: a possible etiopathogenic mechanism. *Arthritis Rheum* 523 2005;52(4):1185-95. doi: 10.1002/art.20998 [published Online First: 2005/04/09]
- 28. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid
 dendritic cell recruitment in target organs of primary Sjögren's syndrome. *Proc Natl Acad Sci U S A* 2006;103(8):2770-5. doi: 10.1073/pnas.0510837103 [published Online First:
 20060213]
- 528 29. Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity
 529 define the origin of interferon signatures in target tissues in rheumatic diseases. *Proc Natl*

530	Acad Sci U S A 2012;109(43):17609-14. doi: 10.1073/pnas.1209724109 [published
531	Online First: 20121008]
532	30. Aota K, Yamanoi T, Kani K, et al. Inhibition of JAK-STAT Signaling by Baricitinib Reduces
533	Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
534	Inflammation 2021;44(1):206-16. doi: 10.1007/s10753-020-01322-w
535	31. Chen X, Jiang S, Zhou Z, et al. Increased expression of interleukin-21-inducible genes in
536	minor salivary glands are associated with primary Sjögren's syndrome disease
537	characteristics. Rheumatology (Oxford) 2021;60(6):2979-89. doi:
538	10.1093/rheumatology/keaa695
539	32. Wakamatsu E, Matsumoto I, Yasukochi T, et al. Overexpression of phosphorylated STAT-
540	1 alpha in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum
541	2006;54(11):3476-84. doi: 10.1002/art.22176
542	33. Pertovaara M, Silvennoinen O, Isomäki P. Cytokine-induced STAT1 activation is increased
543	in patients with primary Sjögren's syndrome. Clin Immunol 2016;165:60-7. doi:
544	10.1016/j.clim.2016.03.010 [published Online First: 20160317]
545	34. Zheng Q, Liu L, Wang B, et al. Phosphorylated signal transducer and activator of
546	transcription proteins 1 in salivary glandular tissue: an important histological marker for
547	diagnosis of primary Sjögren's syndrome. RMD Open 2023;9(1) doi: 10.1136/rmdopen-
548	2022-002694
549	35. Vartoukian SR, Tilakaratne WM, Seoudi N, et al. Dysregulation of the suppressor of
550	cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the
551	aetiopathogenesis of Sjögren's syndrome. Clin Exp Immunol 2014;177(3):618-29. doi:
552	10.1111/cei.12377
553	36. Singh N, Cohen PL. The T cell in Sjogren's syndrome: force majeure, not spectateur. J
554	Autoimmun 2012;39(3):229-33. doi: 10.1016/j.jaut.2012.05.019 [published Online First:
555	20120617]
556	37. Reich NC. STAT3 revs up the powerhouse. Sci Signal 2009;2(90):pe61. doi:
557	10.1126/scisignal.290pe61 [published Online First: 20090929]
558	38. Davies R, Sarkar I, Hammenfors D, et al. Single Cell Based Phosphorylation Profiling
559	Identifies Alterations in Toll-Like Receptor 7 and 9 Signaling in Patients With Primary
560	Sjögren's Syndrome. Front Immunol 2019;10:281. doi: 10.3389/fimmu.2019.00281
561	[published Online First: 20190221]
562	39. Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and
563	thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat
564	2010;13(3):67-78. doi: 10.1016/j.drup.2010.04.001 [published Online First: 20100514]
565	40. Gadina M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to
566	clinical practice. Rheumatology (Oxford) 2019;58(Suppl 1):i4-i16. doi:
567	10.1093/rheumatology/key432
568	41. O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases.
569	Ann Rheum Dis 2013;72 Suppl 2(0 2):ii111-5. doi: 10.1136/annrheumdis-2012-202576
570	42. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. 2017
571	43. Xeljanz (tofacitinib) prescribing information. 2022
572	44. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus
573	placebo in rheumatoid arthritis. N Engl J Med 2012;367(6):508-19. doi:
574	10.1056/NEJMoa1112072

- 45. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis.
 N Engl J Med 2014;370(25):2377-86. doi: 10.1056/NEJMoa1310476
- 46. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy,
 tofacitinib with methotrexate, and adalimumab with methotrexate in patients with
 rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head,
 randomised controlled trial. *Lancet* 2017;390(10093):457-68. doi: 10.1016/s0140-
- 581 6736(17)31618-5 [published Online First: 20170616]
- 47. Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical
 inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib
 and baricitinib. *Ann Rheum Dis* 2021;80(7):865-75. doi: 10.1136/annrheumdis-2020219012 [published Online First: 20210319]
- 48. Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are
 blocked by pharmacological stabilization of the TYK2 pseudokinase domain. *Sci Transl Med* 2019;11(502) doi: 10.1126/scitranslmed.aaw1736

589

590 Figure Legends

591 Figure 1: Bulk sequencing of minor salivary gland and IFN signature

- 592 (A) Overview of MSG biopsy and whole transcriptomic analysis using RNAseq from 22 SjD and
- 593 11 HV. (B) Heatmap illustrating the top 250 DEGs in MSG between SjD and HV highlighting
- 594 multiple ISGs, cytokines, and interleukins, in the DEG. Immune pathway genes, including ISGs
- 595 (e.g., IFI44L, IFI44, MX1, CXCL13), were upregulated whereas canonical salivary genes (e.g.,
- 596 BPIFB2, PIP, ZG16B) were down regulated in SjD. (C) Similarly, a volcano plot showing the
- 597 DEGs between SjD and HV, in which some representative genes were highlighted. MSGs from
- 598 SjD subjects were transcriptionally more active with 2773 upregulated versus 468 downregulated
- 599 genes. (D) Pathway enrichment analysis identified JAK-STAT Pathway as one of the top three
- 600 differentially utilized pathway amongst the 25 significantly enriched pathways in SjD at a *p*-
- 601 adj<0.01 (E, G) Calculated Type-I and Type-II IFN scores revealed 2 through 2.5-fold mean
- 602 increases in SjD MSGs compared to HV. Differences in mean values were compared using the 603 Mann-Whitney U-test at a p < 0.05 deemed significant. (F, H) The activated IFN signature noted
- in our bulk RNAseq positively correlated with FS in the glands. Spearman correlation analysis was
 used to assess the significance between correlated values at a *p* <0.05. MSG, minor salivary gland;
 RNAseq, RNA sequencing; SjD, Sjogren's Disease; HV, healthy volunteer; DEGs, differentially
- 607 expressed genes; ISG, interferon stimulated genes; FS, focus score.
- 608

609 Figure 2: Immunofluorescence microscopy

(A) Overview of MSG biopsy, image acquisition and flow cytometry. (B) MSG IF image showing
upregulated expression of JAK1 and JAK3 in SjD epithelial and infiltrating immune cells. JAK3
was especially enrich in ductal cells. Cellular proportion changes in the SjD MSGs showed greater

613 numbers of immune cells, less numbers of epithelial cells. (C) Mean fluorescence of KRT18, JAK1 614 and JAK3 in SjD and non-SjD showing cellular proportion in the MSGs. Expression of JAK1 615 localized to immune cells (+6%; p<0.0001, Mann-Whitney Test) but JAK3 expression was seen 616 in both epithelial and infiltrating immune cells (35% and 15%, respectively; p<0.0001, Mann-617 Whitney Test). (D) Cellular population change in 7 SjD and 6 non-SjD was characterized by flow 618 cytometry showed reduced numbers of epithelial cells and increased numbers of infiltrating 619 immune cells in SjD MSGs compared to controls. (E) Flow cytometry of MSG represented the 620 frequency of pSTAT proteins: pSTAT1 (2.1-fold, *p*=0.017), pSTAT3(Ser727) (2.2-fold, *p*=0.031), 621 and pSTAT6 (3.3-fold, p=0.112) were higher at baseline in SjD epithelial cells compared to non-622 SjD. Although not reaching the threshold of statistical significance, the frequency of pSTAT 623 proteins (i.e., pSTAT3(Ser727) (p=0.056)) on CD45+ cells showed a similar frequency of pSTAT 624 proteins in the SjD MSG. P value was calculated using Welch's test. MSG, minor salivary gland; 625 IF, immune fluorescent; SjD, Sjogren's Disease; KRT18, Keratin-18.

626

627 Figure 3: Single cell RNAseq and pSTATs frequencies of MSG

628 (A) UMAP embedding of the entire dataset colored by generated clusters labelled by cell type 629 annotation. From all profiled MSG samples from 7 SjD and 5 non-SjD, Leiden clustering identified 630 11 different cell clusters corresponding to mucous (MUC5B) and seromucous acinar cells (MUC7), 631 ductal cells (S100A2), plasma cells (IGHA, IGHG1), fibroblasts (COL1A2), myoepithelial 632 (KRT14), pericytes (ACTA2), B-cells (CD79A), antigen presenting cells (HLA-DRA, CD68), T-633 lymphocytes (CD3D), and erythrocytes (HBB) (n=51736 cells). (B) Differential of cell density 634 showing increased immune cell infiltration in SjD. (C) The top ten DEG in each of the cell types 635 were dominated by ISGs including increased expression B2M, HLA-B, SAA1, IL32, and MGP. (D)

Differential expression of IFN score in SjD and non-SjD, immune cells showed the biggest foldchanges in IFN score were in infiltrating immune cells (e.g., plasma cells: 700-fold, APCs: 400fold; T cells: 300-fold; seromucous cells: 250-fold; ductal epithelial cells: 250-fold) exhibited higher IFN scores. (E) Fold change expression of JAK-STAT genes on all cell types. *JAK1* was the most ubiquitously expressed in MSGs and Seromucous acinar cells showed increased expression of all *JAKs*. UMAP, Uniform manifold approximation and projection; MSG, minor salivary gland; SjD, Sjogren's Disease; DEG, differentially expressed genes.

643

644 Figure 4: Single cell RNAseq and pSTATs frequencies of PBMC

645 (A) Overview of using patient's serum and PBMC for several assays. (B) Somalogic aptamer-646 based 1.3K target proteomics analysis revealed most of proteins were significantly upregulated in 647 serum from SiD in volcano plot showing protein expression, in which some representative genes 648 were highlighted. (C) IFN regulated proteins were found to be upregulated in SjD serum 649 (p < 0.0001). P value was calculated using Kruskal-Wallis test. (D) UMAP embedding of the entire 650 dataset colored by generated clusters labelled by cell type annotation. Leiden clustering identified 651 10 different cell clusters from all profiled PBMC samples from 8 SjD and 6 non-SjD (n=206687 652 cells). (E) The upregulated genes were associated with immune and inflammatory responses revealed by functional annotation analysis from PBMC scRNAseq. (F) Differential expression of 653 654 IFN score, monocytes had the highest expression of ISGs, followed by dendritic cells and then NK 655 cells. SjD, Sjogren's Disease; UMAP, Uniform manifold approximation and projection; RNAseq, 656 RNA sequencing; ISG, interferon stimulated genes.

657

658 Figure 5: Basal pSTATs frequencies in PBMCs

(A-D) Flow cytometry analysis revealed basal pSTATs levels in PBMCs were upregulated in 21
SjD compared to 10 HV. P value was calculated using Welch's test. SjD, Sjogren's Disease; HV,
healthy volunteer.

662

663 Figure 6: Treatment effects of tofacitinib in PBMCs

664 (A) Overview of using PBMC treated by tofacitinib for scRNAseq and FACS. PBMCs were 665 treated with or without 5mM tofacitinib for 1 hour prior to IFN β treatment for 30 minutes or 6 666 hours, respectively. (B) Treatment with tofacitinib blocked STATs phosphorylation status induced 667 by IFN β stimulation in PBMCs from SjD. P value was calculated using Mann-Whitney test. (C) 668 UMAP embedding of the entire dataset colored by generated clusters labelled by 4 general cell 669 type annotations. (D) Differential utilization of IFN signature of each condition showed tofacitinib 670 abolished the IFN β -induced IFN score to baseline level. (E) Volcano plot showing DEGs by 671 pseudobulk analysis across SjD and HV, in which some representative genes were highlighted. T 672 cells (129 genes) and monocytes (61 genes) exhibited greater numbers of downregulated ISGs in 673 the context of tofacitinib. ISGs (e.g., IFIT1, IFIT3) were among the top DEG in all subsets after 674 IFNβ and tofacitinib normalizing this response. RNAseq, RNA sequencing; SjD, Sjogren's 675 Disease; DEG, differentially expressed genes; HV, healthy volunteer; ISG, interferon stimulated 676 genes.

677

678 Figure 7: Treatment effects of tofacitinib in pSGECs

(A) Overview of using pSGEC treated by tofacitinib for IF and RT-qPCR. pSGEC were derived
from fresh MSG biopsies. (B, C) Differential expression of pSTAT1 in pSGECs. Tofacitinib
treatment mitigated IFNβ-induced STAT1 phosphorylation in both the nucleus and cytosol. P

- value was calculated using Kruskal-Wallis test. (D) Expression change of ISGs (*i.e.*, CXCL10,
- 683 ISG15, MX1) on pSGECs showing dose-dependently decreased IFNβ-induced ISGs mRNA
- 684 expression. 5 SjD and 5 HV (n=5 individuals' lines, respectively). 1 SjD and 1 HV samples were
- eliminated from MX1 result. P value was calculated using Mann-Whitney test and Kruskal-Wallis
- 686 test. pSGEC, primary salivary gland epithelial cells; SjD, Sjogren's Disease; HV, healthy
- 687 volunteer; ISG, interferon stimulated genes.













Е

D







CD45+











UMAP_1





С



D

В

20-0.0442 15[.] pSTAT6 (%) 10 5 0 нv SjD

Whole live cells







Cytoplasm









Figure 7

D